WHO ICTRP trial
Regorafenib rollover study
JPRN-jRCT2031230602 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031230602 |
|---|---|
| Public title | Regorafenib rollover study |
| Scientific title | A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint or the main data analysis or has been stopped prematurely. |
| Primary sponsor | Tanigawa Takahiko |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | France;Japan;Korea;Japan;Spain;Japan;Taiwan;Japan |
| Conditions | Solid Tumors |
| Interventions | Drug: Regorafenib (Stivarga, BAY73-4506) Participants will be treated with the regorafenib dose taken during the last cycleof the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160mg orally (p.o.) once daily (qd)… |
| Registration date | Jan 26, 2024 |
| Target size | 1 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: